Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

2 evidence topics · 4 sources

In vitro potency and antifibrotic activity

“CDCs in Deramiocel exert quantifiable anti-fibrotic activity in vitro, mediated through exosome and soluble factors in a dose-dependent manner.” (opens the source at this quote in a new tab)

Preclinical repeated dosing: mdx mice

“early and sustained intervention with mCDCs prevents disease progression for up to 1 year in mdx mice.” (opens the source at this quote in a new tab)
“beneficial effects of hCDC-EVs waned after 6 months” (opens the source at this quote in a new tab)